PARP inhibitors in ovarian cancer

被引：2
|
作者：
Goldlust, Ian S. [1 ]
Guidice, Elena [1 ]
Lee, Jung-min [1 ,2 ]
机构：
[1] NCI, Womens Malignannes Branch, Ctr Canc Res, NIH, Bethesda, MD USA
[2] 10 Ctr Dr,Bldg 10,Room 6B12, Bethesda, MD 20892 USA
来源：
SEMINARS IN ONCOLOGY | 2024年 / 51卷 / 1-2期
关键词：
Epithelial ovarian cancer; Homologous recombination deficiency; BRCA mutation; PARP inhibitor; PLATINUM-BASED CHEMOTHERAPY; PHASE-III TRIAL; OLAPARIB MONOTHERAPY; DOUBLE-BLIND; NONPLATINUM CHEMOTHERAPY; MAINTENANCE THERAPY; SEROUS OVARIAN; OPEN-LABEL; RUCAPARIB; CARCINOMA;
D O I：
10.1053/j.seminoncol.2024.01.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency. In this review, we provide a historical overview of PARPi use in EOC and discuss recent updates on overall survival data, highlighting their impact on regulatory approvals. We explore their potential as combination regimens with antiangiogenic and cell-cycle checkpoint inhibitors, as well as other small molecule inhibitors, to overcome resistance mechanisms and enhance therapeutic efficacy, providing a future perspective on the use of PARPis in EOC treatment. Published by Elsevier Inc.
引用
收藏
页码：45 / 57
页数：13
相关论文
共 50 条
  • [1] PARP Inhibitors in Ovarian Cancer
    Mittica, Gloria
    Ghisoni, Eleonora
    Giannone, Gaia
    Genta, Sofia
    Aglietta, Massimo
    Sapino, Anna
    Valabrega, Giorgio
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2018, 13 (04) : 392 - 410
  • [2] PARP inhibitors in ovarian cancer
    David Cibula
    Judith Balmaña
    British Journal of Cancer, 2015, 113 : S1 - S2
  • [3] PARP Inhibitors in Ovarian Cancer
    da Costa, Alexandre
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (16): : 1572 - 1573
  • [4] PARP Inhibitors for Ovarian Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1535): : 200 - 202
  • [5] PARP INHIBITORS IN OVARIAN CANCER
    Calvert, H.
    Curtin, N.
    Plummer, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 23 - 23
  • [6] PARP inhibitors in ovarian cancer
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 : 40 - 44
  • [7] PARP inhibitors in ovarian cancer
    Franzese, Elisena
    Centonze, Sara
    Diana, Anna
    Carlino, Francesca
    Guerrera, Luigi Pio
    Di Napoli, Marilena
    De Vita, Ferdinando
    Pignata, Sandro
    Ciardiello, Fortunato
    Orditura, Michele
    CANCER TREATMENT REVIEWS, 2019, 73 : 1 - 9
  • [8] PARP INHIBITORS IN OVARIAN CANCER THERAPY
    Pisula, Agata
    Sienicka, Agnieszka
    Dobrowolska-Redo, Agnieszka
    Kacperczyk-Bartnik, Joanna
    Romejko-Wolniewicz, Ewa
    PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (02): : 71 - 74
  • [9] PARP Inhibitors in Ovarian Cancer Treatment
    Spriggs, David R.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2197 - 2198
  • [10] PARP Inhibitors in Ovarian Cancer: A Review
    David M. O’Malley
    Thomas C. Krivak
    Nashwa Kabil
    Jiefen Munley
    Kathleen N. Moore
    Targeted Oncology, 2023, 18 : 471 - 503
12345